{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:25:33Z","timestamp":1794273933620,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this study, we identified the multifaceted effects of atezolizumab, a specific monoclonal antibody against PD-L1, in tumor suppression except for restoring antitumor immunity, and investigated the promising ways to improve its efficacy. Atezolizumab could inhibit the proliferation and induce immune-independent apoptosis of osteosarcoma cells. With further exploration, we found that atezolizumab could impair mitochondria of osteosarcoma cells, resulting in increased release of reactive oxygen species and cytochrome-c, eventually leading to mitochondrial-related apoptosis via activating JNK pathway. Nevertheless, the excessive release of reactive oxygen species also activated the protective autophagy of osteosarcoma cells. Therefore, when we combined atezolizumab with autophagy inhibitors, the cytotoxic effect of atezolizumab on osteosarcoma cells was significantly enhanced in vitro. Further in vivo experiments also confirmed that atezolizumab combined with chloroquine achieved the most significant antitumor effect. Taken together, our study indicates that atezolizumab can induce mitochondrial-related apoptosis and protective autophagy independently of the immune system, and targeting autophagy is a promising combinatorial approach to amplify its cytotoxicity.<\/jats:p>","DOI":"10.1038\/s41419-021-03449-6","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:31:35Z","timestamp":1612819895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9864-5952","authenticated-orcid":false,"given":"Zhuochao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-9773","authenticated-orcid":false,"given":"Weibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"3449_CR1","first-page":"6502","volume":"16","author":"Z Nie","year":"2018","unstructured":"Nie, Z. & Peng, H. Osteosarcoma in patients below 25 years of age: an observational study of incidence, metastasis, treatment and outcomes. Oncol. Lett. 16, 6502\u20136514 (2018).","journal-title":"Oncol. Lett."},{"key":"3449_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-0284-9_1","volume":"152","author":"G Ottaviani","year":"2009","unstructured":"Ottaviani, G. & Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res. 152, 3\u201313 (2009).","journal-title":"Cancer Treat. Res."},{"key":"3449_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-319-07323-1_4","volume":"162","author":"DD Moore","year":"2014","unstructured":"Moore, D. D. & Luu, H. H. Osteosarcoma. Cancer Treat. Res. 162, 65\u201392 (2014).","journal-title":"Cancer Treat. Res."},{"key":"3449_CR4","doi-asserted-by":"publisher","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","volume":"21 Suppl 7","author":"J Ritter","year":"2010","unstructured":"Ritter, J. & Bielack, S. S. Osteosarcoma. Ann. Oncol. 21 Suppl 7, vii320\u2013vii325 (2010).","journal-title":"Ann. Oncol."},{"key":"3449_CR5","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.4049\/jimmunol.1401572","volume":"193","author":"S Ostrand-Rosenberg","year":"2014","unstructured":"Ostrand-Rosenberg, S., Horn, L. A. & Haile, S. T. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J. Immunol. 193, 3835\u20133841 (2014).","journal-title":"J. Immunol."},{"key":"3449_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467\u2013477 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"3449_CR7","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","volume":"35","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J. Clin. Oncol. 35, 2781\u20132789 (2017).","journal-title":"J. Clin. Oncol."},{"key":"3449_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).","journal-title":"Lancet"},{"key":"3449_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3449_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3449_CR11","doi-asserted-by":"publisher","unstructured":"Wang, J. et al. Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma. J. Immunother. https:\/\/doi.org\/10.1097\/CJI.0000000000000281 (2019).","DOI":"10.1097\/CJI.0000000000000281"},{"key":"3449_CR12","doi-asserted-by":"publisher","unstructured":"Liu, Z. et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Aging 12, https:\/\/doi.org\/10.18632\/aging.102679 (2020).","DOI":"10.18632\/aging.102679"},{"key":"3449_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep30093","volume":"6","author":"P Koirala","year":"2016","unstructured":"Koirala, P. et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci. Rep. 6, 30093 (2016).","journal-title":"Sci. Rep."},{"key":"3449_CR14","doi-asserted-by":"publisher","first-page":"111836","DOI":"10.18632\/oncotarget.22912","volume":"8","author":"E Palmerini","year":"2017","unstructured":"Palmerini, E. et al. Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8\/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget 8, 111836\u2013111846 (2017).","journal-title":"Oncotarget"},{"key":"3449_CR15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493\u20131501 (2017).","journal-title":"Lancet Oncol."},{"key":"3449_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677\u2013704 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"3449_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ijc.30834","volume":"141","author":"S Almozyan","year":"2017","unstructured":"Almozyan, S. et al. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K\/AKT pathway activation. Int. J. Cancer 141, 1402\u20131412 (2017).","journal-title":"Int. J. Cancer"},{"key":"3449_CR18","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","volume":"111","author":"T Azuma","year":"2008","unstructured":"Azuma, T. et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635\u20133643 (2008).","journal-title":"Blood"},{"key":"3449_CR19","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark, C. A. et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 76, 6964\u20136974 (2016).","journal-title":"Cancer Res."},{"key":"3449_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"3449_CR21","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","volume":"23","author":"BA Inman","year":"2017","unstructured":"Inman, B. A., Longo, T. A., Ramalingam, S. & Harrison, M. R. Atezolizumab: a PD-L1-blocking antibody for bladder cancer. Clin. Cancer Res. 23, 1886\u20131890 (2017).","journal-title":"Clin. Cancer Res."},{"key":"3449_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-018-0129-0","volume":"12","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. CD24 identifies nucleus pulposus progenitors\/notochordal cells for disc regeneration. J. Biol. Eng. 12, 35 (2018).","journal-title":"J. Biol. Eng."},{"key":"3449_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bbrc.2017.05.086","volume":"488","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Hypoxia-inducible factor-lalpha mediates aggrecan and collagen Pi expression via NOTCH1 signaling in nucleus pulposus cells during intervertebral disc degeneration. Biochem. Biophys. Res. Commun. 488, 554\u2013561 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3449_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"3449_CR25","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","volume":"28","author":"A Necchi","year":"2017","unstructured":"Necchi, A. et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann. Oncol. 28, 3044\u20133050 (2017).","journal-title":"Ann. Oncol."},{"key":"3449_CR26","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"3449_CR27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ijc.25397","volume":"128","author":"F Shi","year":"2011","unstructured":"Shi, F. et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer 128, 887\u2013896 (2011).","journal-title":"Int. J. Cancer"},{"key":"3449_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Investig. 124, 687\u2013695 (2014).","journal-title":"J. Clin. Investig."},{"key":"3449_CR29","doi-asserted-by":"publisher","unstructured":"Zheng, F. et al. PD-L1 promotes self-renewal and tumorigenicity of malignant melanoma initiating cells. Biomed. Res. Int. 2017, 1293201, https:\/\/doi.org\/10.1155\/2017\/1293201 (2017).","DOI":"10.1155\/2017\/1293201"},{"key":"3449_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2084-1","volume":"10","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Artesunate induces mitochondria-mediated apoptosis of human retinoblastoma cells by upregulating Kruppel-like factor 6. Cell Death Dis. 10, 862 (2019).","journal-title":"Cell Death Dis."},{"key":"3449_CR31","doi-asserted-by":"publisher","unstructured":"Kim, S. J., Kim, H. S. & Seo, Y. R. Understanding of ROS-inducing strategy in anticancer therapy. Oxid. Med. Cell. Longev. 2019, 5381692, https:\/\/doi.org\/10.1155\/2019\/5381692 (2019).","DOI":"10.1155\/2019\/5381692"},{"key":"3449_CR32","doi-asserted-by":"publisher","unstructured":"Chung, L. Y. et al. Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy. J. Cell. Mol. Med. https:\/\/doi.org\/10.1111\/jcmm.14898 (2019).","DOI":"10.1111\/jcmm.14898"},{"key":"3449_CR33","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1002\/cam4.881","volume":"5","author":"F Shan","year":"2016","unstructured":"Shan, F., Shao, Z., Jiang, S. & Cheng, Z. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways. Cancer Med. 5, 3166\u20133175 (2016).","journal-title":"Cancer Med."},{"key":"3449_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.33594\/000000052","volume":"52","author":"S Almasi","year":"2019","unstructured":"Almasi, S. et al. TRPM2 silencing causes G2\/M arrest and apoptosis in lung cancer cells via increasing intracellular ROS and RNS levels and activating the JNK pathway. Cell Physiol. Biochem. 52, 742\u2013757 (2019).","journal-title":"Cell Physiol. Biochem."},{"key":"3449_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fcell.2020.00245","volume":"8","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Non-esterified fatty acid induce dairy cow hepatocytes apoptosis via the mitochondria-mediated ROS-JNK\/ERK signaling pathway. Front. Cell Dev. Biol. 8, 245 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"3449_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/cdd.2014.150","volume":"22","author":"G Filomeni","year":"2015","unstructured":"Filomeni, G., De Zio, D. & Cecconi, F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 22, 377\u2013388 (2015).","journal-title":"Cell Death Differ."},{"key":"3449_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000047804","volume":"11","author":"H Sauer","year":"2001","unstructured":"Sauer, H., Wartenberg, M. & Hescheler, J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol. Biochem. 11, 173\u2013186 (2001).","journal-title":"Cell Physiol. Biochem."},{"key":"3449_CR38","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10495-007-0069-5","volume":"12","author":"L Papa","year":"2007","unstructured":"Papa, L., Gomes, E. & Rockwell, P. Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death. Apoptosis 12, 1389\u20131405 (2007).","journal-title":"Apoptosis"},{"key":"3449_CR39","doi-asserted-by":"publisher","unstructured":"Chiou, J. T. et al. Compound C induces autophagy and apoptosis in parental and hydroquinone-selected malignant leukemia cells through the ROS\/p38 MAPK\/AMPK\/TET2\/FOXP3 axis. Cell Biol. Toxicol. https:\/\/doi.org\/10.1007\/s10565-019-09495-3 (2020).","DOI":"10.1007\/s10565-019-09495-3"},{"key":"3449_CR40","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1096\/fj.201700662RR","volume":"32","author":"P Sukumaran","year":"2018","unstructured":"Sukumaran, P., Sun, Y., Antonson, N. & Singh, B. B. Dopaminergic neurotoxins induce cell death by attenuating NF-kappaB-mediated regulation of TRPC1 expression and autophagy. FASEB J. 32, 1640\u20131652 (2018).","journal-title":"FASEB J."},{"key":"3449_CR41","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1096\/fj.201700477R","volume":"32","author":"W Yang","year":"2018","unstructured":"Yang, W. et al. Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. FASEB J. 32, 1222\u20131235 (2018).","journal-title":"FASEB J."},{"key":"3449_CR42","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/15548627.2017.1280223","volume":"13","author":"CA Clark","year":"2017","unstructured":"Clark, C. A., Gupta, H. B. & Curiel, T. J. Tumor cell-intrinsic CD274\/PD-L1: a novel metabolic balancing act with clinical potential. Autophagy 13, 987\u2013988 (2017).","journal-title":"Autophagy"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03449-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03449-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03449-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:26:18Z","timestamp":1669919178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03449-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["3449"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03449-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This protocol was approved by the Ethics Committee of Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"164"}}